Status: Recruiting
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Participants needed: 55
Trial details
Phase: Phase 2Age: 18-99Biological sex: FemaleType: InterventionalSponsor: University of OklahomaUpdated: Oct 22, 2025Locations: 4
Eligibility criteria
Female subjects ≥ 18 years of age. [+18]
Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy. [+21]